Since GrM specifically targets the FVIII-binding capacity of VWF (Fig. 5), therapeutic administration of GrM concentrates in plasma may potentially lower plasma FVIII levels in patients with high FVIII and a concomitant tendency for developing thrombosis, while leaving the pro-hemostatic function of VWF intact. This evidence concerns the gene VWF and deep vein thrombosis.